Brokers Issue Forecasts for TELO FY2024 Earnings

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) – Equities researchers at Zacks Small Cap issued their FY2024 earnings per share estimates for shares of Telomir Pharmaceuticals in a research note issued on Thursday, November 21st. Zacks Small Cap analyst B. Sorensen expects that the company will earn ($0.54) per share for the year. The consensus estimate for Telomir Pharmaceuticals’ current full-year earnings is ($0.54) per share. Zacks Small Cap also issued estimates for Telomir Pharmaceuticals’ Q4 2024 earnings at ($0.05) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.18) EPS.

Telomir Pharmaceuticals Stock Up 5.9 %

Shares of TELO opened at $4.49 on Monday. Telomir Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $20.72. The firm’s 50 day moving average is $5.03 and its 200-day moving average is $5.00.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Beaird Harris Wealth Management LLC raised its position in Telomir Pharmaceuticals by 212.9% during the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after purchasing an additional 9,950 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth $241,000. Suncoast Equity Management boosted its stake in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after buying an additional 26,803 shares in the last quarter. Barclays PLC boosted its stake in Telomir Pharmaceuticals by 325.1% in the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock valued at $45,000 after buying an additional 5,367 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Telomir Pharmaceuticals by 259.8% in the third quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock valued at $1,533,000 after acquiring an additional 172,382 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.